LAMEA Epigenetics Market

LAMEA Epigenetics Market Size, Share & Industry Trends Analysis Report By Application (Oncology and Non-Oncology), By Product, By End User, By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-8720 Publication Date: May-2022 Number of Pages: 95
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Latin America, Middle East and Africa Epigenetics Market would witness market growth of 17.8% CAGR during the forecast period (2022-2028).

Numerous illnesses and other health indicators, including malignancies, respiratory diseases, cardiovascular diseases, reproductive problems, autoimmune disorders, and cognitive dysfunction afflictions, may have a direct or indirect link with epigenetic pathways. Heavy metals, pesticides, tobacco smoke, hormones, radiation, viruses, environmental variables, and basic nutrients, all of which contribute to such situations, are on the rise, bolstering the growth of the market.

Growing risk factors and the accompanying increase in cancer cases, higher R&D activities, rising pharmaceutical and biotechnology industries, epigenetics application expanse, and other causes are some of the market's growth catalysts. In addition, massive adoption is being fueled by the development of highly sensitive and selective tests, instrumentation, and a concomitant increase in processing capacity. The development of DNA and RNA modifying enzymes including acetylases, reverse transcriptase, methyltransferases, ligases, and other protein-modifying enzymes has sparked a lot of interest and accelerated the epigenetics market acceptance.

The medical utility of genetic markers for illness prediction and prevention in heart and other muscle cells has been restricted. This is the uncharted area in the field of risk classification, prevention, and treatment, and it has piqued the interest of the cardiovascular research community. Although current enthusiasm for its clinical applications greatly outnumbers available data, the subject of cardiovascular epigenetics is quickly increasing. Epigenetics is interesting as an idea because processes like DNA methylation and histone changes connect the genotype to the environment.

Cancer is a new health problem in Africa that needs to be treated properly if the incidence and fatality rates are to be reduced. According to some estimates, population expansion and aging would result in a 70% increase in new cancer occurrences by 2030. This persistent condition has coexisted in Africa with newly found communicable diseases like Malaria, Ebola, AIDS, and COVID19. Despite the fact that cancer mortality rates have surpassed those of AIDS, TB, and malaria combined, there is still a lack of commitment in Africa to combat cancer. Indeed, the majority of emphasis is focused on communicable diseases, but numerous non-communicable diseases, such as cancer, face similar issues.

The Brazil market dominated the LAMEA Epigenetics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $51.7 Million by 2028. The Argentina market is estimated to grow at a CAGR of 18.4% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 17.4% during (2022 - 2028).

Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Epigenetics Market is Predict to reach $2.9 Billion by 2028, at a CAGR of 14.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Application

  • Oncology
  • Non-Oncology

By Product

  • Kits
  • Reagents
  • Enzymes
  • Instruments

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Abcam plc
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck Group
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Zymo Research
  • Active Motif, Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo